BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 28225974)

  • 1. Do you know this syndrome? Hand-foot syndrome.
    Braghiroli CS; Ieiri R; Ocanha JP; Paschoalini RB; Miot HA
    An Bras Dermatol; 2017; 92(1):131-133. PubMed ID: 28225974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Docetaxel-induced palmoplantar erythrodysesthesia syndrome and long-lasting multiple nail changes.
    Akoglu G
    Indian J Pharmacol; 2014; 46(2):225-7. PubMed ID: 24741199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T-DM1-related carotenoderma and hand-foot syndrome.
    Dholaria B; Srinivasan S
    Lancet; 2015 Apr; 385(9977):1509-10. PubMed ID: 25933279
    [No Abstract]   [Full Text] [Related]  

  • 4. Chemotherapy-induced acral erythema with involvement of the face and neck: A case report.
    Ozkol HU; Calka O; Bulut G
    Toxicol Ind Health; 2016 May; 32(5):791-4. PubMed ID: 24311625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence and implications of chemotherapy related hand-foot syndrome.
    Nikolaou V; Syrigos K; Saif MW
    Expert Opin Drug Saf; 2016 Dec; 15(12):1625-1633. PubMed ID: 27718746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy-induced hand-foot syndrome and nail changes: a review of clinical presentation, etiology, pathogenesis, and management.
    Miller KK; Gorcey L; McLellan BN
    J Am Acad Dermatol; 2014 Oct; 71(4):787-94. PubMed ID: 24795111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Hand-foot syndrome].
    Asao T; Kaira K
    Nihon Rinsho; 2015 Feb; 73 Suppl 2():454-7. PubMed ID: 25831802
    [No Abstract]   [Full Text] [Related]  

  • 8. Rapidly developing facial and intertriginous hyperpigmentation with acral erythema after docetaxel infusion.
    Eryılmaz MK; Tazegul G; Ünal B; Müsri FY; Güzel HG; Coşkun HŞ
    J Cancer Res Ther; 2021; 17(1):293-294. PubMed ID: 33723176
    [No Abstract]   [Full Text] [Related]  

  • 9. Hand-foot syndrome and its impact on daily activities in breast cancer patients receiving docetaxel-based chemotherapy.
    Hsu YH; Shen WC; Wang CH; Lin YF; Chen SC
    Eur J Oncol Nurs; 2019 Dec; 43():101670. PubMed ID: 31586645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differentiating hand-foot syndrome from tinea in patients receiving chemotherapy.
    Wang JZ; Cowley A; McLellan BN
    Acta Oncol; 2016 Aug; 55(8):1061-4. PubMed ID: 27181134
    [No Abstract]   [Full Text] [Related]  

  • 11. Development and Validation of the Korean Version of Hand-Foot Skin Reaction and Quality of Life Questionnaire (HF-QoL-K).
    Nam SH; Choi HJ; Kang WD; Kim SM; Lim MC; Park SY; Kim JS; Kim BG; Bae DS; Lee JW; Kim TJ; Song T
    J Korean Med Sci; 2016 Dec; 31(12):1969-1975. PubMed ID: 27822937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rare occurrence of hand-foot syndrome due to paclitaxel: A rare case report.
    Kataria PS; Kendre PP; Patel AA; Tahiliani N; Bhargav V; Parekh H
    Indian J Pharmacol; 2018; 50(5):284-286. PubMed ID: 30636833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy-induced erythrodysesthesia of the breast.
    Alcalde-Castro J; Soto-Perez-de-Celis E; Reyes-Gutiérrez E; Orozco-Topete R; León-Rodríguez E; Chávarri-Guerra Y
    Breast J; 2018 Sep; 24(5):828-830. PubMed ID: 29738105
    [No Abstract]   [Full Text] [Related]  

  • 14. Paclitaxel-induced acral erythema.
    Richards KN; Ivan D; Rashid RM; Chon SY
    Arch Dermatol; 2012 Nov; 148(11):1333-4. PubMed ID: 23165853
    [No Abstract]   [Full Text] [Related]  

  • 15. Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib.
    McLellan B; Kerr H
    Dermatol Ther; 2011; 24(4):396-400. PubMed ID: 21910797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sunitinib-induced hand-foot syndrome in a renal cell carcinoma: a sclerodermatous and rheumatoid arthritis-like case.
    Ohtsuka T
    J Dermatol; 2012 Nov; 39(11):943-4. PubMed ID: 22257303
    [No Abstract]   [Full Text] [Related]  

  • 17. Hand-foot syndrome caused by docetaxel with no recurrence after switch to paclitaxel, a different taxane.
    Corazza M; Minghetti S; Borghi A; Virgili A; Ballardini P
    Int J Dermatol; 2014 Mar; 53(3):e180-2. PubMed ID: 23621794
    [No Abstract]   [Full Text] [Related]  

  • 18. Chemotherapy and loss of fingerprint; problematic issue beyond the side effect.
    Mumyakmaz A; Altundag K
    J BUON; 2016; 21(6):1566-1567. PubMed ID: 28039728
    [No Abstract]   [Full Text] [Related]  

  • 19. Palmar-plantar erythrodysesthesia.
    Gupta A; Mehta A; Khanna S
    BMJ Case Rep; 2015 Sep; 2015():. PubMed ID: 26359464
    [No Abstract]   [Full Text] [Related]  

  • 20. Sorafenib-induced grade III hand-foot skin reaction with ulcerative dermatitis on scrotum, penis, and earlobe.
    Sirka CS; Sahu K; Pradhan S; Rout AN
    Indian J Dermatol Venereol Leprol; 2019; 85(6):623-626. PubMed ID: 31584016
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.